Pharsight

1. Avandamet patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5741803	SB PHARMCO	Substituted thiazolidinedionle derivatives	Apr, 2015 (9 years ago)
US7358366	SB PHARMCO	Thiazolidinedione derivative and its use as antidiabetic	Apr, 2020 (4 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5741803 (Pediatric)	SB PHARMCO	Substituted thiazolidinedionle derivatives	Oct, 2015 (8 years ago)
US6166042	SB PHARMCO	Pharmaceutical composition	Jun, 2016 (7 years ago)
US5965584	SB PHARMCO	Pharmaceutical composition	Jun, 2016 (7 years ago)
US6288095	SB PHARMCO	Compounds	Feb, 2017 (7 years ago)
US6288095 (Pediatric)	SB PHARMCO	Compounds	Aug, 2017 (6 years ago)
US7358366 (Pediatric)	SB PHARMCO	Thiazolidinedione derivative and its use as antidiabetic	Oct, 2020 (3 years ago)
US8236345	SB PHARMCO	Composition and use	Oct, 2022 (1 year, 6 months ago)

Market Authorisation Date: 25 August, 2003

Treatment: Treatment of type 2 diabetes mellitus; First line therapy for type 2 diabetes mellitus

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/ 500 mg, 2 mg/ 500mg 4 mg/ 500 mg 2 mg/ 1000 mg 4 mg/ 1000 mg	22 Oct, 2004	1		11 Feb, 2017	Eligible

Strength	Dosage	Availability
500MG;EQ 2MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
500MG;EQ 1MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
500MG;EQ 4MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
1GM;EQ 2MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
1GM;EQ 4MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5741803	SB PHARMCO	Substituted thiazolidinedionle derivatives	Apr, 2015 (9 years ago)
US7358366	SB PHARMCO	Thiazolidinedione derivative and its use as antidiabetic	Apr, 2020 (4 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5741803 (Pediatric)	SB PHARMCO	Substituted thiazolidinedionle derivatives	Oct, 2015 (8 years ago)
US7358366 (Pediatric)	SB PHARMCO	Thiazolidinedione derivative and its use as antidiabetic	Oct, 2020 (3 years ago)

Market Authorisation Date: 23 November, 2005

Treatment: To improve glycemic control in patients with type 2 diabetes mellitus

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/4 mg 2 mg/4 mg 4 mg/4 mg	22 Dec, 2006	1	01 Apr, 2016	21 Oct, 2015	Extinguished
8 mg/2 mg 8 mg/4 mg	30 May, 2008	1	01 Apr, 2016	19 Oct, 2020	Eligible

Strength	Dosage	Availability
4MG;4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
2MG;4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
1MG;4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
4MG;8MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
2MG;8MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued